Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Mathieu Coudert"'
Autor:
Tadej Battelino, Thomas Danne, Steve V. Edelman, Pratik Choudhary, Eric Renard, Jukka Westerbacka, Bhaswati Mukherjee, Valerie Pilorget, Mathieu Coudert, Richard M. Bergenstal
Publikováno v:
Diabetes, Obesity and Metabolism. 25:545-555
Autor:
Rory J. McCrimmon, Alice Y.Y. Cheng, Gagik Galstyan, Khier Djaballah, Xuan Li, Mathieu Coudert, Juan P. Frias
Publikováno v:
Diabetes, Obesity and Metabolism. 25:68-77
For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once-daily iGlarLixi versus a multiple-injection BI + r
Autor:
Rory J. McCrimmon, Alice Y.Y. Cheng, Robert Ritzel, Gagik Galstyan, Khier Djaballah, Xuan Li, Mathieu Coudert, Juan Frías
Publikováno v:
Diabetologie und Stoffwechsel.
Autor:
Tadej, Battelino, Thomas, Danne, Steve V, Edelman, Pratik, Choudhary, Eric, Renard, Jukka, Westerbacka, Bhaswati, Mukherjee, Valerie, Pilorget, Mathieu, Coudert, Richard M, Bergenstal
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 25(2)
To use continuous glucose monitoring (CGM)-based time-in-range (TIR) as a primary efficacy endpoint to compare the second-generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla-300) and insulin degludec 100 U/ml (IDeg-100) in adults w
Autor:
William H. Polonsky, Francesco Giorgino, Julio Rosenstock, Katherine Whitmire, Elisheva Lew, Mathieu Coudert, Agustina Alvarez, Charlie Nicholls, Rory J. McCrimmon
Publikováno v:
Diabetes, obesitymetabolism. 24(12)
To assess patient-reported outcomes (PROs) in the SoliMix trial, which compared the efficacy and safety of iGlarLixi versus BIAsp 30 in people with type 2 diabetes (T2D).SoliMix (EudraCT: 2017-003370-13), a 26-week, open-label study, randomized (1:1)
Autor:
RORY J. MCCRIMMON, ALICE Y. CHENG, GAGIK R. GALSTYAN, KHIER DJABALLAH, XUAN LI, MATHIEU COUDERT, JUAN PABLO FRIAS
Publikováno v:
Diabetes. 71
Introduction: Indirect evidence suggests iGlarLixi is as efficacious as basal insulin (BI) + rapid acting insulin (RAI) for management of type 2 diabetes (T2D) . However, there are no direct comparisons of iGlarLixi (once-daily [QD]) vs. a BI+RAI reg
Autor:
NIAZ KHAN, AMIR TIROSH, ANIL BHANSALI, HERNANDO VARGAS-URICOECHEA, STEWART B. HARRIS, AUDE ROBOREL DE CLIMENS, MARIA AILEEN N. MABUNAY, MATHIEU COUDERT, VALERIE PILORGET, GAGIK R. GALSTYAN
Publikováno v:
Diabetes. 71
Patients' satisfaction is a key determinant of treatment adherence and persistence, for optimal management of T2D. ATOS, a 12-month prospective observational study conducted in Asia, Middle East, North Africa, Latin America, and Eastern Europe, showe
Autor:
Mohamed Hassanein, Rachid Malek, Inass Shaltout, Rakesh Kumar Sahay, Mehmet Akif Buyukbese, Khier Djaballah, Valerie Pilorget, Mathieu Coudert, Saud Al Sifri
Publikováno v:
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 17:102707
Autor:
Gagik R. Galstyan, Amir Tirosh, Hernando Vargas-Uricoechea, Maria Aileen Mabunay, Mathieu Coudert, Mubarak Naqvi, Valerie Pilorget, Niaz Khan
Publikováno v:
Diabetes therapy : research, treatment and education of diabetes and related disorders. 13(6)
The clinical benefits of insulin glargine 300 U/mL (Gla-300) have been confirmed in randomised clinical trials (EDITION programme and BRIGHT) and real-world studies in the USA and Western Europe. ATOS evaluated the real-world effectiveness and safety
Autor:
Maria Aileen N. Mabunay, Niaz Khan, Valerie Pilorget, Gagik Radikovich Galstyan, Hernando Vargas-Uricoechea, Amir Tirosh, Mathieu Coudert
Publikováno v:
Diabetes. 70
ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naive adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral antihyperglycemic drug. In this subgroup analysis participants were strat